clinical trial · NCT05655507
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
Biogen·phase1·completed·n = 19
Major Depressive DisorderZuranolone
brief summary
The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
started
Apr 19, 2023
primary completion
Oct 18, 2024
completion
Oct 18, 2024
last updated
Mar 26, 2025
detailed description
This study was previously posted by Sage Therapeutics. In December 2024, sponsorship of the trial was transferred to Biogen.
official title
A Phase 1, Study to Evaluate the Pharmacokinetics and Safety of Zuranolone in Adolescents (12 to 17 Years of Age) With Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol